Claims for Patent: 9,920,127

Summary for Patent: 9,920,127

Title:	Methods of treating pain with compositions comprising RANK/RANKL antagonists and related compounds
Abstract:	Disclosed herein are methods of treating pain using RANK/RANKL antagonists.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	15/619,293
Patent Claims:	1. A method of treating or relieving osteoarthritis pain, low back pain, or pain from complex regional pain syndrome in a mammal in need thereof, comprising administering a pharmaceutical composition comprising: a) antibody means for antagonizing RANK/RANKL binding; and b) one or more physiologically acceptable carriers, excipients or diluents. 2. The method of claim 1, wherein the antibody means for antagonizing RANK/RANKL binding comprises an anti-RANKL antibody. 3. The method of claim 1, wherein the antibody means for antagonizing RANK/RANKL binding competes with denosumab for binding to RANKL. 4. The method of claim 1, wherein the antibody means is a monoclonal antibody. 5. The method of claim 4, wherein the monoclonal antibody is a human antibody, a humanized antibody, or a chimeric antibody. 6. The method of claim 5, wherein the monoclonal antibody is a human antibody. 7. The method of claim 5, wherein the monoclonal antibody is a humanized antibody. 8. The method of claim 1, wherein the antibody means for antagonizing RANK/RANKL binding comprises a RANKL-binding fragment. 9. The method of claim 8, wherein the RANKL-binding fragment is a Fab, a Fab', a F(ab')2, a Fv fragment, a diabody, a linear antibody, or a single-chain antibody molecule. 10. The method of claim 9, wherein the RANKL-binding fragment is a single-chain antibody molecule. 11. The method of claim 1, wherein the antibody means for antagonizing RANK/RANKL binding partially or fully blocks, inhibits, or neutralizes a biological activity of RANKL. 12. The method of claim 1, wherein the antibody means for antagonizing RANK/RANKL binding comprises a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3; and b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 4. 13. The method of claim 1, wherein the mammal is a human. 14. The method of claim 1, wherein about 0.05 mg/kg to about 3 mg/kg of the antibody means is administered to the mammal within a four week period. 15. The method of claim 14, where about 0.1 mg/kg to about 20 mg/kg of the antibody means is administered. 16. The method of claim 1, wherein the antibody means is administered no more than once a week. 17. The method of claim 1, wherein the antibody means is administered daily, weekly, monthly, every three months, every six months, or every year. 18. The method of claim 1, wherein the method is a method of relieving osteoarthritis pain. 19. The method of claim 18, wherein the osteoarthritis pain affects a knee. 20. The method of claim 1, wherein the method is a method of relieving pain from complex regional pain syndrome. 21. The method of claim 1, wherein the method is a method of relieving low back pain. 22. The method of claim 1, wherein the mammal experiences pain relief within about three months after the antibody means is first administered. 23. The method of claim 1, wherein the mammal experiences pain relief for at least 24 hours. 24. The method of claim 1, wherein the excipient comprises polyethylene glycol or a metal ion. 25. The method of claim 1, wherein the carrier comprises polyacetic acid, polyglycolic acid, a hydrogel, dextran, a liposome, a microemulsion, a micelle, a unilamellar vesicle, a multilamellar vesicle, an erythrocyte ghost, or a spheroblast. 26. The method of claim 1, wherein the diluent comprises sterile water, sucrose solution, neutral buffered saline, or saline mixed with conspecific serum albumin. 27. The method of claim 1, wherein the excipient comprises a buffer, an antioxidant, ascorbic acid, an amino acid, a polypeptide of less than about 10 residues, a protein, a carbohydrate, glucose, sucrose, dextrin, a chelator, EDTA, or glutathione. 28. The method of claim 25, wherein the liposome comprises monoglycerides, diglycerides, cholesterols, sulfatides, lysolecithins, phospholipids, saponins, or bile acids.

Details for Patent 9,920,127

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2034-06-11
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2034-06-11
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2034-06-11